Overexpression of Jagged2 can be triggered either by promoter hypomethylation,12 through aberrant expression of the ubiquitin ligase Skeletrophin13 or by loss of SMRT/NCoR2 corepressor, which results in abnormal acetylation of the Jagged2 promoter.14 In MM, Notch confers resistance to apoptotic stimuli and protects against chemotherapy-induced toxicity.15, 16 Nefedova et al.15 described that Notch signalling is involved in de novo drug resistance triggered by bone marrow stroma. The gene discussed is JAG2; the disease is Miyoshi myopathy.